Rob Medcalf Is Working On a Novel Thrombolytic Drug
Monash Translational Medicine shared on LinkedIn:
”Time is brain’ when a person has a stroke.
But even when a patient receives medical attention within 60 minutes, that’s often not enough: tPA, the main drug currently used to treat acute ischemic stroke (the most common stroke type in Australia) isn’t effective for the majority of patients.
Professor Rob Medcalf, of the Australian Centre for Blood Diseases based at Monash Translational Medicine, is working on a novel thrombolytic (clot-busting) drug that could give many more stroke patients a better chance of recovery.
He’s been awarded two Monash University grants – from the Monash Research Impact Fund (MIRF) and the MNHS Commercialisation Incubator Program (MCIP) – to progress development of the drug.
”We desperately need more drug options to treat stroke, for the many patients who can’t go on TPA for reasons ranging from the other medications they’re on, to the short window for effective treatment,” Rob says.
‘These grants will help us address some of the challenges of bringing new drugs to market.”’
-
Aug 19, 2026, 09:12Charlie Berman: Infections Following Mechanical Thrombectomy for Acute Stroke
-
Aug 19, 2026, 08:39Choosing the Right P2Y12 Inhibitor After PCI – JAMA Cardiology
-
Aug 19, 2026, 08:05Charles Cohen: Why Women Wait Years Longer for a Bleeding Disorder Diagnosis
-
Aug 19, 2026, 07:42Chukwuemeka Amarachi: Thalassemia – Types, Diagnosis and Management
-
Aug 19, 2026, 07:15Ajay Kumar: Real-World Outcomes of Plasma Exchange in NMOSD
-
Aug 19, 2026, 07:02Amer Zeidan: Managing Anemia in Lower-Risk MDS
-
Aug 19, 2026, 06:24GT Connect – Connecting the GT Community – Glanzmann’s Research Foundation
-
Aug 19, 2026, 01:43Elvira Grandone: Cancer and Thrombosis in Women – Where Do We Stand?
-
Aug 19, 2026, 01:37Ifeanyichukwu Ifechidere: Coagulation Knowledge – A Core Skill in Internal Medicine